A recent study showed that the expression of miR-34a increases in nonalcoholic steatohepatitis [NASH] patients, and confirmed the validity of miR-34a in diagnosing NASH in comparison with alanine aminotransferase (ALT) in patient with nonalcoholic fatty liver disease (NAFLD) (36). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.